Vertebral fractures cascade: potential causes and risk factors
We performed a study to identify potential causes and risk factors of vertebral fracture cascade. Vertebral fracture cascade is a severe clinical event in patients with bone fragility. Only half of patients have an identified cause of secondary osteoporosis.
Vertebral fracture (VF) is the most common osteoporotic fracture, and a strong risk factor of subsequent VFs leading to VF cascade (VFC). We prompted a study to identify potential causes and risk factors of VFC.
VFC observations were collected retrospectively between January 2016 and April 2017. VFC was defined as an occurrence of at least three VFs within 1 year.
We included in 10 centers a total of 113 patients with VFC (79.6% of women, median age 73, median number of VFs in the cascade, 5). We observed 40.5% and 30.9% of patients with previous major fractures and a previous VF, respectively, and 68.6% with densitometric osteoporosis; 18.9% of patients were currently receiving oral glucocorticoids and 37.1% in the past.
VFC was attributed by the physician to postmenopausal osteoporosis in 54% of patients. A secondary osteoporosis associated with the VFC was diagnosed in 52 patients: glucocorticoid-induced osteoporosis (25.7%), non-malignant hemopathies (6.2%), alcoholism (4.4%), use of aromatase inhibitors (3.6%), primary hyperparathyroidism (2.7%), hypercorticism (2.7%), anorexia nervosa (2.7%), and pregnancy and lactation-associated osteoporosis (1.8%). A total of 11.8% of cases were reported following a vertebroplasty procedure. A total of 31.5% patients previously received an anti-osteoporotic treatment. In six patients, VFC occurred early after discontinuation of an anti-osteoporotic treatment, in the year after the last dose effect was depleted: five after denosumab and one after odanacatib.
The results of this retrospective study showed that only half of VFC occurred in patients with a secondary cause of osteoporosis. Prospective studies are needed to further explore the determinants of this severe complication of osteoporosis.
KeywordsCascade Osteoporosis Risks factors Vertebral fractures
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflicts of interest
Dr. Breuil received grant support and lecture fees from Amgen, Novartis, Chugai, and Lilly. Dr. Briot has received research grants or honoraria from Amgen, Lilly, Medtronic, and MSD. Dr. Cortet has received research grants or honoraria from Amgen, Expanscience, Ferring, Lilly, Medtronic, MSD, Mylan, Novartis, Roche diagnostics, Théramex, and UCB. Dr. Thomas received grant support, lecture fees, and consulting fees from Amgen, Merck Sharp & Dohme, and UCB Pharma; grant support and lecture fees from Chugai and Pfizer; consulting fees from Expanscience, Gilead Sciences, LCA, Thuasne, and Medac; grant support and consulting fees from HAC Pharma; grant support from Novartis; lecture fees from AbbVie, Biogen, and Bristol-Myers Squibb; and lecture fees and consulting fees from Eli Lilly and Teva Pharmaceutical Industries. Dr. Roux has received grants and/or honoraria from Alexion, Amgen, MSD, UCB. Dr. Che, Dr. Paccou, Dr. Chapuis, Dr. Debiais, Dr. Mehsen-Cetre, Dr. Javier, and Dr. Loiseau Peres have no disclosure to declare.
- 6.Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718. https://doi.org/10.1007/s00198-015-3455-9 CrossRefPubMedGoogle Scholar
- 12.Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 361:569–579. https://doi.org/10.1056/NEJMoa0900563 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Blasco J, Martinez-Ferrer A, Macho J, San Roman L, Pomés J, Carrasco J, Monegal A, Guañabens N, Peris P (2012) Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: a 12-month randomized follow-up, controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res 27:1159–1166. https://doi.org/10.1002/jbmr.1564 CrossRefGoogle Scholar
- 17.Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res Off J Am Soc Bone Miner Res 32:1291–1296. https://doi.org/10.1002/jbmr.3110 CrossRefGoogle Scholar
- 19.Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JEB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res Off J Am Soc Bone Miner Res 33:190–198. https://doi.org/10.1002/jbmr.3337 CrossRefGoogle Scholar
- 22.Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17. https://doi.org/10.1016/j.bone.2017.08.003 CrossRefPubMedGoogle Scholar
- 27.Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, Vassalli L, Rodella F, Formenti AM, Frara S, Maroldi R, Berruti A, Simoncini E, Giustina A (2017) Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97:147–152. https://doi.org/10.1016/j.bone.2017.01.013 CrossRefPubMedGoogle Scholar
- 29.Piot JM, Royer M, Schmidt-Tanguy A, Hoppé E, Gardembas M, Bourrée T, Hunault M, François S, Boyer F, Ifrah N, Renier G, Chevailler A, Audran M, Chappard D, Libouban H, Mabilleau G, Legrand E, Bouvard B (2015) Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. Blood Cancer J 5:e345. https://doi.org/10.1038/bcj.2015.71 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, Zamò A, Bonadonna P, Kunnathully V, Adami S, Gatti D (2016) Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 27:2411–2421. https://doi.org/10.1007/s00198-016-3539-1 CrossRefPubMedGoogle Scholar
- 32.Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Frances C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841. https://doi.org/10.1136/ard.2009.124511 CrossRefPubMedGoogle Scholar
- 40.Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res Off J Am Soc Bone Miner Res 14:821–828. https://doi.org/10.1359/jbmr.19126.96.36.1991 CrossRefGoogle Scholar
- 44.Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677–683. https://doi.org/10.1530/EJE-16-1027 CrossRefPubMedGoogle Scholar